Glenmark Pharmaceuticals has reported result for first quarter ended June 30, 2025 (Q1FY26).
The company has reported 27.22% fall in its net profit at Rs 330.23 crore for the quarter ended June 30, 2025 as compared to Rs 453.73 crore for the same quarter in the previous year. However, the total income of the company increased by 3.32% at Rs 2464.26 crore for Q1FY26 as compared to Rs 2385.19 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported 86.23% drop in its net profit at Rs 46.87 crore for Q1FY26 as compared to Rs 340.27 crore for the same quarter in the previous year. However, the total income of the company increased by 0.46% at Rs 3290.88 crore for Q1FY26 as compared to Rs 3275.68 crore for the corresponding quarter previous year.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: